论文部分内容阅读
目的 探讨端粒酶活性在乳腺癌的诊断价值及其临床病理学相关性。方法 应用端粒酶ＰＣＲ 酶联免疫吸附法定量检测４０ 例乳癌，３１ 例乳腺良性病变和９ 例正常乳腺组织端粒酶活性，同时与硝酸银染色定性检测对比。结果 端粒酶在乳癌、乳腺良性病变、正常乳腺组织表达的阳性率分别为７０ ％ （２８／４０） ，２９ ％ （９／３１） 和０ ％ （０／９） 。按定量检测其ＯＤ值分别为０．６０３，０．２５８ 和０．０３，３ 组之间均有显著性差异（ Ｐ ＜ ０ ．００１） 。端粒酶活性在乳癌中心和癌旁组织分别为０．６０３ 和０．２９３（ Ｐ ＜ ０ ．００１） 。按ＴＮＭ 分期，Ⅲ期（０．７８０ ±０．３９４） 高于Ⅱ期（０．５１１ ±０．４４７）（ Ｐ ＜ ０ ．０５） 。ＰＲ 阴性组（０．７８６ ±０．４４７） 高于ＰＲ 阳性组（０．５０１ ±０．３９３）（ Ｐ ＜ ０ ．０５） 。结论 良、恶性乳腺肿瘤端粒酶活性有显著性差异，可作为乳癌诊断的辅助指标之一；端粒酶活性与临床分期和ＰＲ 受体相关，提示端粒酶可作为反映乳癌侵袭性和预后的指标。
Objective To investigate the diagnostic value of telomerase activity in breast cancer and its clinicopathological correlation. Methods The telomerase activity of 40 cases of breast cancer, 31 cases of benign breast lesions and 9 cases of normal breast tissue were detected by telomerase PCR and enzyme linked immunosorbent assay. The results were qualitatively compared with silver nitrate staining. Results The positive rates of telomerase expression in breast cancer, benign breast lesions and normal breast tissue were 70% (28/40), 29% (9/31) and 0% (0/9). The OD values were quantitatively detected as 0.603, 0.258 and 0.03, respectively, and there was a significant difference between the 3 groups (P < 0.0001). The telomerase activity was 0.603 and 0.293 in the breast cancer center and the adjacent tissue respectively (P < 0.001). By TNM stage, stage III (0.780 ± 0.394) was higher than stage II (0.511 ± 0.447) (P < 0.05). The PR negative group (0.786 ± 0.447) was higher than the PR positive group (0.501 ± 0.393) (P < 0.05). Conclusion The telomerase activity in benign and malignant mammary gland tumors is significantly different and can be used as an auxiliary marker for the diagnosis of breast cancer. The telomerase activity is related to clinical stage and PR receptors, suggesting that telomerase may reflect the invasion and prognosis of breast cancer. index of.